Meeting
2017 ASCO Quality Care Symposium
Early national dissemination of abiraterone and enzalutamide for advanced prostate cancer in Medicare Part D.
Authors
Megan Veresh Caram
University of Michigan Comprehensive Cancer Center, Ann Arbor, MI
Megan Veresh Caram, Tudor Borza, Hye-Sung Min, Jennifer J. Griggs, David Christopher Miller, Brent K. Hollenbeck, Bhramar Mukherjee, Ted A. Skolarus
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Cost, Value, and Policy in Quality; Practice of Quality
Track
Cost, Value, and Policy in Quality,Practice of Quality
Sub Track
Specialty and Manpower Issues
Citation
J Clin Oncol 35, 2017 (suppl 8S; abstract 35)
DOI
10.1200/JCO.2017.35.8_suppl.35
Abstract #
35
Poster Bd #
B19
Abstract Disclosures
Similar Posters
Poster
2020 Genitourinary Cancers Symposium
Financial hardship among Medicare beneficiaries prescribed oral targeted therapies for advanced prostate cancer.
First Author: Megan Veresh Caram
Poster
2018 Genitourinary Cancers Symposium
Contemporary trends in abiraterone and enzalutamide prescription by provider specialty.
First Author: Daniel Pucheril
Poster
2023 ASCO Genitourinary Cancers Symposium
Differences in concomitant medication prescribing before and after novel hormonal therapy (NHT) in men with prostate cancer: A population-based study.
First Author: Amy Yang
Poster
2021 ASCO Annual Meeting
Survival of veterans treated with enzalutamide and abiraterone in advanced prostate cancer.
First Author: Martin W. Schoen